ARGX Price Prediction Next Week
Analysis and Insights
News Sentiment and Recent Developments:
Analyst Upgrade: Morgan Stanley has raised the price target for Argenx (ARGX) from EUR 635 to EUR 715, maintaining an Overweight rating. This upgrade reflects increased confidence in the company's growth prospects.
Clinical Trial Announcements: Argenx will present new clinical trial and real-world data for Vyvgart and Vyvgart Hytrulo at the American Academy of Neurology annual meeting. This presentation could highlight sustained clinical improvements and safety over extended treatment periods.
Safety Profile: The largest safety data set on FcRn blocking demonstrates a consistent and favorable safety profile for VYVGART and VYVGART Hytrulo, supporting their long-term efficacy and safety in treating gMG and CIDP.
Technical Indicators Analysis:
- RSI: The RSI_14 is 32.12, indicating the stock is in a bearish zone but approaching oversold levels, suggesting potential for a rebound.
- MACD: The MACD (-8.56) and MACD Histogram (-3.44) indicate bearish momentum, but the signal line (-5.13) suggests slowing downward momentum.
- Fibonacci Levels: The stock is trading below the pivot level of 621.54, with resistance at 643.73 and support at 585.64.
Price Projection:
Based on the analyst upgrade and positive clinical data, the stock is expected to rebound. The target price for the next trading week is $630.
Recommendation:
Buy Argenx (ARGX) as the positive news and technical indicators suggest a potential rebound.
ARGX Similar Chart Price Prediction
The price of ARGX is predicted to go up -9.98%, based on the high correlation periods with FIBK. The similarity of these two price pattern on the periods is 94.79%.
ARGX
FIBK
Down: -9.98%Similarity: 94.79%
ARGX Revenue Forecast
ARGX EPS Forecast
ARGX FAQs
What is ARGX revenue forecast for next quarter？
What is ARGX eps forecast for next quarter？
ARGX VS S&P500
Novel FcRn inhibitor Vyvgart is a pipeline in a product, currently approved in myasthenia gravis but in testing in multiple additional indications.
Vyvgart's approval in myasthenia gravis made it the first-to-market FcRn-targeting drug, putting Argenx in a strong position to entrench itself in the market before competitors arrive.
With exclusive access to Halozyme's subcutaneous drug delivery technology, Argenx can improve the convenience of Vyvgart and potentially differentiate its drug from future competition.
ARGX Analyst's Forecast
Yatin Suneja
Guggenheim
Strong Buy
2025-03-10
Price Target
$775 → $1,100
Upside
+92.64%
Guggenheim raised the firm's price target on Argenx to $1,100 from $775 and keeps a Buy rating on the shares. Argenx has set "clear and bold goals with their 2030 agenda," which include reaching 50,000 patients on treatment in 10 labeled indications and bringing five new molecules to Phase 3 by 2030, notes the analyst. The firm's analysis suggests the company could "nearly double its market capitalization" within five years, the analyst tells investors.
Joel Beatty
Baird
Hold
2025-03-04
Price Target
$650 → $680
Upside
+8.54%
Joon Lee
Truist Securities
Strong Buy
2025-01-14
Price Target
$660 → $700
Upside
+5.14%
